Opioid Analgesics

Respiratory depression from opioids doesn't announce itself with alarms — it starts with sedation. If you miss the sedation, you miss your window to intervene.

The most dangerous opioid adverse effect is respiratory depression. The progression is predictable: pain relief → sedation → respiratory depression. A sedation scale is your earliest warning tool — increasing drowsiness precedes a falling respiratory rate. Hold the dose and notify the provider if respirations fall below 12 breaths/min or the patient becomes difficult to arouse. Beyond respiratory depression, expect constipation in virtually every patient on scheduled opioids — it's the one side effect the body never develops tolerance to. Proactive bowel regimens (stool softeners, stimulant laxatives, adequate fluids) start when opioids start. Other predictable effects include nausea/vomiting (worst in the first 24–72 hours, often resolves), urinary retention, orthostatic hypotension, pruritus, and miosis (pinpoint pupils). Nursing priorities: monitor respiratory rate and sedation level before and after each dose, assess pain using a standardized scale, keep naloxone accessible, raise side rails, implement fall precautions due to CNS depression, and teach the patient to change positions slowly. Patient teaching must include avoiding alcohol and other CNS depressants, not driving until effects are known, and reporting difficulty breathing or excessive drowsiness immediately.

Key Distinctions

Don't confuse sedation (the early warning) with adequate pain relief (the goal) — a patient who is increasingly sleepy needs reassessment, not celebration. Students often think constipation resolves with continued use like nausea does — it does not; bowel regimens are lifelong while on opioids. Pruritus from opioids is histamine-mediated, not a true allergy — don't automatically document an allergy for itching alone.

Clinical Pearl

Sedation before desaturation — assess level of consciousness before you count respirations. The sleepy patient is your red flag, not the number on the pulse ox.

MOA & Use

Opioid analgesics work by binding mu receptors in the brain, spinal cord, and peripheral tissues, mimicking endogenous endorphins. Mu-receptor activation produces analgesia, euphoria, sedation, and respiratory depression — all from the same binding event. Full agonists (morphine, hydromorphone, fentanyl, oxycodone) have no ceiling for analgesia; increasing the dose increases the effect, which is why they manage moderate-to-severe pain but carry overdose risk. Mixed agonist-antagonists (butorphanol, nalbuphine) activate kappa receptors while blocking or limiting mu activity, giving them a ceiling effect and making them useful for moderate pain — but they can precipitate withdrawal in a patient already on a full agonist. Partial agonists (buprenorphine) bind mu with high affinity but produce submaximal activation, used primarily for opioid use disorder treatment and chronic pain. Morphine remains the gold standard for acute severe pain and is the reference drug for equianalgesic dosing. Fentanyl is 50–100 times more potent than morphine, making it ideal for rapid-onset IV or transdermal use. Hydromorphone is preferred in renal impairment because it produces fewer neurotoxic metabolites than morphine.

Key Distinctions

Don't confuse full agonists (no analgesic ceiling) with mixed agonist-antagonists (ceiling effect, can trigger withdrawal in opioid-dependent patients). Students mix up potency and efficacy: fentanyl is more potent (smaller dose needed), but morphine achieves the same maximum pain relief — potency affects dose size, not effectiveness. Buprenorphine is a partial agonist, not an antagonist — it still produces analgesia.

Clinical Pearl

Full agonist = no ceiling for pain relief or respiratory depression. Mixed agonist-antagonist + full agonist on board = instant withdrawal. Never combine them.

Tolerance, Dependence & Addiction

Tolerance, physical dependence, and addiction are three distinct phenomena that students must separate cleanly. Tolerance is a pharmacologic adaptation: mu-opioid receptors downregulate with prolonged exposure, so the same dose produces less analgesia and fewer side effects over time. A tolerant patient legitimately needs higher doses. Physical dependence is a neuroadaptive state — abrupt discontinuation triggers withdrawal (diaphoresis, tachycardia, cramping, anxiety, yawning, piloerection) within 6–24 hours of the last dose. Taper opioids by 20–25% every 1–2 days to prevent this. Addiction (substance use disorder) is a behavioral pattern of compulsive use despite harm — it is NOT the same as dependence. Equianalgesia is the conversion framework for switching opioids safely. Oral morphine 30 mg ≈ oral hydromorphone 4 mg ≈ oral oxycodone 20 mg ≈ IV morphine 10 mg. When converting, reduce the calculated equianalgesic dose by 25–50% because cross-tolerance between opioids is incomplete — the new drug's receptors are fresh. Nurses must verify conversions, monitor pain scores closely during transitions, and advocate when doses seem dangerously high or inadequately low.

Key Distinctions

Don't confuse physical dependence with addiction — a post-surgical patient who experiences withdrawal symptoms is dependent, not addicted. Students mistake tolerance for drug-seeking; tolerance is a predictable physiologic response, not a behavioral choice. When converting opioids, the full equianalgesic dose is NOT given — always reduce by 25–50% for incomplete cross-tolerance.

Clinical Pearl

Dependence lives in the receptors; addiction lives in the behavior. A patient can have one without the other — your assessment must distinguish them.